Moderna Stock News

A 2023 stock market recap is a tale of highs and lows. We entered the year after a Fed tightening cycle proved restrictive but seemingly unsuccessful as inflation continued while rates rose.

Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.

With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in t

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conferenc

Investors need to understand and be able to steer clear of companies that have a poor future outlook. Whether from reduced financial guidance, overall financial instability, management issues, or rele

Is Moderna stock a buy after announcing promising results for its Merck-tied cancer vaccine? Is MRNA stock a buy right now?

BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.

Investors have shied away from buying Moderna shares as demand for its coronavirus vaccine declines. But the biotech has set high goals, aiming to release many new products during the next few years.

The bulls look to be firmly in control of the stock market now. The U.S. Federal Reserve has pivoted away from its monetary tightening regime and signaled three interest rate cuts in 2024.

Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of

Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.

Moderna Inc.'s MRNA, +9.25% investigational vaccine for respiratory syncytial virus is 84% effective against the lower respiratory tract illness linked with the virus, according to phase 3 study data

Moderna (MRNA) shares are surging Thursday after the company announced positive mid-stage trial data showing its experimental cancer vaccine, used in combination with Merck's (MRK) immunotherapy Keytr

Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.

CNBC's Angelica Peebles joins 'Power Lunch' to report on Moderna's experimental cancer vaccine.